Atossa stock prediction

Stock Price Forecast

The 1 analysts offering 12-month price forecasts for Atossa Therapeutics Inc have a median target of 7.50, with a high estimate of 7.50 and a low estimate of 7.50. The median estimate represents a +535.59% increase from the last price of 1.18.

What is the forecast for Atossa Therapeutics (Atos) stock?

Our ATOS stock forecast indicates that shares will see a 46.11% price increase over the next year and reach a price of $ 1.53 by April 27, 2023. How to read and forecast Atossa Therapeutics, Inc. stock price movements?

What are analysts’price targets for Atossa Genetics’stock?

1 analysts have issued 1 year price targets for Atossa Genetics’ shares. Their predictions range from $9.00 to $9.00. On average, they expect Atossa Genetics’ stock price to reach $9.00 in the next twelve months.

What is the price targets for Atos?

The high price target for ATOS is $9.00 and the low price target for ATOS is $9.00. There are currently 1 hold rating for the stock, resulting in a consensus rating of “Hold.”.

Will Atossa Therapeutics (Atos) outperform or underperform the S&P 500?

(Add your “underperform” vote.) Atossa Therapeutics has received 67.27% “outperform” votes from our community. MarketBeat’s community ratings are surveys of what our community members think about Atossa Therapeutics and other stocks. Vote “Outperform” if you believe ATOS will outperform the S&P 500 over the long term.


Will Atossa Therapeutics go back up?

Atossa Therapeutics Inc quote is equal to 1.005 USD at 2022-06-07. Based on our forecasts, a long-term increase is expected, the “ATOS” stock price prognosis for 2027-06-04 is 2.167 USD. With a 5-year investment, the revenue is expected to be around +115.63%. Your current $100 investment may be up to $215.63 in 2027.


Should I invest in Atossa?

Is ATOSSA THERAPEUTICS Stock a good buy in 2022, according to Wall Street analysts? The consensus among 1 Wall Street analyst covering (NASDAQ: ATOS) stock is to Strong Buy ATOS stock.


Why is Atossa Therapeutics stock dropping?

Shares of Atossa Therapeutics (NASDAQ: ATOS) were tumbling 22.8% as of 11:36 a.m. EDT on Wednesday. The decline came after the company announced final results from its phase 2 clinical study evaluating oral endoxifen in treating breast cancer with administration between diagnosis and surgery.


Is Atos being shorted?

Short Shares Availability This table shows the number of shares of US:ATOS available to be shorted at a leading prime brokerage.


Is the Atossa therapeutic?

Seattle-based Atossa Therapeutics (NASDAQ: ATOS) is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need. Atossa’s current focus is on breast cancer and COVID-19.


Is seel a buy?

Is SEELOS THERAPEUTICS Stock a good buy in 2022, according to Wall Street analysts? The consensus among 3 Wall Street analysts covering (NASDAQ: SEEL) stock is to Strong Buy SEEL stock.


Will Atossa stock go up?

Stock Price Forecast The 1 analysts offering 12-month price forecasts for Atossa Therapeutics Inc have a median target of 7.50, with a high estimate of 7.50 and a low estimate of 7.50. The median estimate represents a +621.15% increase from the last price of 1.04.


Is Atos overvalued?

Ascendiant Capital is very positive about ATOS and gave it a “” rating on Sep 17, 2020….Predicted Opening Price for Atossa Genetics Inc. of Monday, June 6, 2022.Fair opening price June 6, 2022Current price$0.99$1.02 (Overvalued)


How many employees does Atossa have?

Latest UpdatesEmployees (est.) (Mar 2020)6(-66%)Revenue (FY, 2015)$1.8 K(-99%)Share Price (May 2022)$0.9(+8%)Cybersecurity ratingAMore


Stock Price Forecast


Analyst Recommendations

The 2 analysts offering 12-month price forecasts for Atossa Therapeutics Inc have a median target of 6.38, with a high estimate of 8.75 and a low estimate of 4.00. The median estimate represents a +405.95% increase from the last price of 1.26.


Atossa Therapeutics After-Hype Price Prediction Density Analysis

The current consensus among 2 polled investment analysts is to Buy stock in Atossa Therapeutics Inc. This rating has held steady since February, when it was unchanged from a Buy rating. Move your mouse over past
months for detail


Atossa Therapeutics Estimiated After-Hype Price Volatility

As far as predicting the price of Atossa Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range.


Atossa Therapeutics Stock Price Prediction Analysis

In the context of predicting Atossa Therapeutics’ stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Atossa Therapeutics’ historical news coverage.


Atossa Therapeutics Hype Timeline

Have you ever been surprised when a price of a company such as Atossa Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Atossa Therapeutics backward and forwards among themselves.


Atossa Therapeutics Related Hype Analysis

Atossa Therapeutics is presently traded for 1.25. The entity has historical hype elasticity of -0.02 and average elasticity to hype of competition of -0.01. Atossa is estimated to decline in value after the next headline with price expected to drop to 1.22. The average volatility ofmedia hypeimpact on the company stock price is over 100%.


Atossa Therapeutics Additional Predictive Modules

Having access to credible news sources related to Atossa Therapeutics’ direct competition is more important than ever and may enhance your ability to predict Atossa Therapeutics’ future price movements.


About Atossa Therapeutics

Most predictive techniques to examine Atossa price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Atossa using various technical indicators.


Atossa Therapeutics (NASDAQ:ATOS) Frequently Asked Questions

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests.


Atossa Therapeutics (NASDAQ:ATOS) Price Target and Consensus Rating

Atossa Therapeutics’ stock was trading at $0.88 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ATOS stock has increased by 43.2% and is now trading at $1.26.
View which stocks have been most impacted by COVID-19.


Analyst Price Target Consensus

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst’s rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy).


Analyst Ratings By Month

Sign-up to receive the latest news and ratings for ATOS and its competitors with MarketBeat’s FREE daily newsletter.


Average Share Price and Price Target by Month

The chart below shows how a company’s ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.


Atossa Therapeutics (NASDAQ:ATOS) Analyst Ratings Frequently Asked Questions

The chart below shows how a company’s share price and consensus price target have changed over time. The dark blue line represents the company’s actual price. The lighter blue line represents the stock’s consensus price target.

Leave a Comment